Abstract
Objective: To measure the effects of repeated intramuscular botulinum toxin type A (BTX-A) for focal upper-limb spasticity of stroke patients on health utility and quality of life. Design: Multicenter, open-label, repeated-dose study. Setting: 35 North-American stroke research centers. Participants: 279 stroke patients. Intervention: Up to 5 intramuscular BTX-A (100–600U) injections given to wrist, finger, and elbow flexors. Main Outcome Measures: The Stroke-Adapted Sickness Impact Profile (SIP-SA; score range, 0 [no dysfunction] to 100 [maximum dysfunction]) and the EuroQol (EQ-5D) visual analog score (VAS; score range, 0 [worst imaginable health] to 100 [best imaginable health]) were evaluated at baseline, and weeks 6, 12, 24, 30, 36, and 48 after first intervention.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
